Sublingual NMN vs Capsules: Is the Absorption Hype Real?
Sublingual NMN is sold as '2–3x more bioavailable' than capsules — but no human trial proves it, and the studies showing NMN works used swallowed capsules.
Updated
5 min read · 10 sources
On this page
Open any NMN marketplace and you'll see the same pitch: sublingual NMN — powder, troches, or dissolving tablets held under the tongue — is "2 to 3 times more bioavailable" than capsules because it "bypasses your gut and goes straight into the bloodstream." It's a tidy story with a real-sounding mechanism. The problem is that the specific claim has never been tested head-to-head in humans, and almost every study that established NMN does anything at all used a swallowed oral dose, not a sublingual one. Here's how to separate the legitimate physiology from the marketing math.
The pitch, and the kernel of truth inside it
Featured partner
CoreAge Rx
From $93/mo
Check availabilityRead our reviewAffiliate link. We may earn a commission at no extra cost to you.
Affiliate partner
Peter MD
Physician-prescribed injectable NAD+, sold as a course rather than a monthly plan
See Peter MDThe sublingual rationale isn't invented out of nothing. The lining under your tongue is thin and richly supplied with blood vessels, so some drugs absorbed there enter the bloodstream directly and skip "first-pass" metabolism in the gut and liver. That's a genuine, well-described route — it's why nitroglycerin and certain hormones are given sublingually 1. For a small subset of molecules, sublingual delivery really can beat swallowing.
But that same pharmacology literature is clear about the catch: transmucosal absorption is selective. It favors molecules that are small, reasonably fat-soluble (lipophilic), stable in saliva, and able to stay in contact with the mucosa long enough to cross it 1. Water solubility and charge can limit passive movement across the mouth lining, and some of a dose held there can be swallowed. The relative contribution of each route requires measurement for the actual formulation. That description fits NAD+ itself far better than it fits NMN, which is worth holding onto when a seller offers a prescription sublingual NAD+ tablet as the needle-free option: needle-free is a comfort argument, not an absorption one.
Sublingual vs capsule readout
Swipe table to compare all columns →
| Sublingual NMN | Capsule / powder NMN | |
|---|---|---|
| Bioavailability claim | '2–3x' — no head-to-head human trial | Makes no special claim |
| Fit for the route | Large, charged, water-soluble = poor sublingual candidate | Swallowed dosing — tested in humans |
| Human evidence | No published sublingual-vs-capsule trial | Multiple trials: raises blood NAD+ |
| Sensible reason to pick | You dislike swallowing pills | Proven, well-studied delivery route |
Why NMN is not an obvious sublingual win
NMN is a phosphorylated, water-soluble, charged molecule — closer to the "poor sublingual candidate" profile than the "ideal" one. And what we know about how the body actually handles NMN points to the gut, not the mouth, as the real entry point.
When healthy men took a single oral dose of NMN, it was rapidly metabolized; the compounds that rose in the blood were the downstream nicotinamide metabolites, consistent with NMN being processed during and after gut absorption rather than entering intact 2. A separate Slc12a8 transporter study used cellular and mouse experiments, including mouse intestinal tissue; it is not a human comparison of sublingual and swallowed NMN 3. Human oral-dosing studies show metabolism after swallowing, but do not establish what fraction of a sublingual product crosses the mouth lining. The relevant missing evidence is a direct human route comparison.
None of this proves sublingual NMN does nothing. It means the headline absorption advantage is an assumption, not a finding.
The evidence that NMN works at all came from swallowed doses
This is the part the marketing skips. The trials that show oral NMN reliably raises blood NAD+ — the one thing NMN is genuinely proven to do — used ordinary swallowed oral doses, typically capsules or powder taken by mouth and swallowed:
- A dose-ranging randomized trial in healthy middle-aged adults found oral NMN raised NAD+ dose-dependently and was well tolerated 4.
- A controlled study showed oral NMN safely and efficiently increased blood NAD+ in healthy subjects 5.
- Pharmaceutical-grade NMN (MIB-626), given orally, robustly increased circulating NAD+ and its metabolome 6.
- A 12-week trial using 250 mg/day of oral NMN reported a rise in NAD+ alongside modest functional and sleep-quality changes in older adults 7.
Strength of evidence
- Swallowed oral NMN → raises blood NAD+Strong evidence
Multiple randomized/controlled trials using capsules or powder.
- Human oral NMN metabolismModerate evidence
Human swallowed-dose studies; the Slc12a8 transporter study is preclinical, not a human route comparison.
- Sublingual NMN → '2–3x' bioavailability vs capsulesNone evidence
No published head-to-head human trial exists.
- Sublingual → better felt outcomes than capsulesNone evidence
Untested; the benefit trials all used swallowed NMN.
In other words, the benefits people cite to justify buying sublingual NMN were actually demonstrated with swallowed NMN. If anything, the burden of proof runs the other way: a sublingual product should have to show it matches or beats the route that the evidence base was built on — and so far, none has, in a published human comparison.
"2–3x bioavailability": where does that number even come from?
It's worth being precise, because this figure is everywhere. There is no published, peer-reviewed human trial measuring blood NAD+ (or NMN) after sublingual NMN versus capsule NMN in the same people. Reviews of NMN supplementation note that absorption and individual metabolic responses vary and remain incompletely characterized 8 — which is the opposite of a settled "2–3x" multiplier. When a brand quotes a precise bioavailability advantage with no citation to a head-to-head study, treat the number as a marketing estimate, not data.
Liposomal evidence does not answer the sublingual question
Liposomal encapsulation and holding a product under the tongue are different delivery strategies. A published 2025 trial compared SINTO liposomal NMN with ordinary NMN and placebo in 15 men, five per group, at 350 mg/day for four weeks. It reported a larger NAD+ response with the tested liposomal formulation, but did not study sublingual dosing, identify Renue retail capsules as the intervention or establish a clinical benefit over ordinary NMN. It therefore cannot validate the “2–3x” sublingual claim. 10
What the marketing gets right vs. wrong
To be fair to the category: the general concern behind it is legitimate. NAD+ precursors do face absorption and metabolism hurdles, and a lot of NMN is dismantled and rebuilt indirectly rather than entering cells whole — much of the early enthusiasm rests on animal work, such as long-term NMN slowing age-associated decline in mice 9, which doesn't transfer cleanly to humans. So caring about delivery isn't silly. The error is jumping from "absorption is a real issue" to "therefore this specific sublingual format is 2–3x better," with no human data closing the gap. That's the same move the liposomal NAD+ marketing makes — a real delivery problem used to sell an unproven delivery fix.
Bottom line
Sublingual NMN rests on a real mechanism applied to a poorly suited molecule, with no head-to-head human trial behind its headline "2–3x bioavailability" claim — and the studies proving NMN raises NAD+ at all used swallowed capsules or powder. If you prefer a sublingual format because you dislike swallowing pills, that's a perfectly fine reason to choose it; just don't pay a premium expecting a proven absorption upgrade, because that upgrade hasn't been demonstrated. For choosing a product on the factors that actually matter — third-party purity testing and dose transparency — see the best NMN supplements rated by evidence; for how much to take and when, see our NAD+ dosage guide. For the full picture of what NAD+ supplementation has and hasn't shown, start with our pillar guide to the NAD+ evidence and the evidence-rated best NAD+ supplements hub.
Frequently asked questions
Is sublingual NMN really more bioavailable than capsules?
There's no published human trial proving it. The '2–3x more bioavailable' figure you see is a marketing estimate, not data from a head-to-head study measuring blood NAD+ after sublingual versus capsule NMN in the same people. NMN is also a large, charged, water-soluble molecule, which makes it a poor candidate for sublingual absorption in the first place. Human trials support swallowed dosing; the intestinal transporter study used preclinical experiments and does not establish human sublingual absorption.
Did the studies showing NMN works use sublingual or capsules?
Swallowed oral doses — capsules or powder taken by mouth. Every trial establishing that NMN reliably raises blood NAD+ used a swallowed oral form, not a sublingual one. So the benefits cited to sell sublingual NMN were actually demonstrated with the swallowed version.
Should I take NMN under my tongue or just swallow it?
If you dislike swallowing pills, a sublingual format is a perfectly reasonable preference — but don't pay extra expecting a proven absorption upgrade, because that hasn't been demonstrated in humans. Swallowed capsules or powder use the well-studied gut route that the evidence base relies on. Either way, consistency and product quality (third-party testing) matter far more than the format.
Why is NMN a poor candidate for sublingual absorption?
Sublingual absorption favors molecules that are small, fat-soluble, stable in saliva, and able to linger on the mucosa. NMN is relatively large, water-soluble, and charged — closer to the profile of a poor sublingual candidate. Some of a sublingual dose can be swallowed, but the fraction absorbed through the mouth versus the gut has not been established by the cited NMN studies.
References
- Lam JK, Xu Y, Worsley A, Wong IC (2014). Oral transmucosal drug delivery for pediatric use. Advanced Drug Delivery Reviews. https://pubmed.ncbi.nlm.nih.gov/23999459/
- Irie J, Inagaki E, Fujita M, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal. https://pubmed.ncbi.nlm.nih.gov/31685720/
- Grozio A, Mills KF, Yoshino J, et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism. https://pubmed.ncbi.nlm.nih.gov/31131364/
- Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. https://pubmed.ncbi.nlm.nih.gov/36482258/
- Okabe K, Yaku K, Uchida Y, et al. (2022). Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in Nutrition. https://pubmed.ncbi.nlm.nih.gov/35479740/
- Pencina KM, Lavu S, Dos Santos M, et al. (2023). MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The Journals of Gerontology: Series A. https://pubmed.ncbi.nlm.nih.gov/35182418/
- Morifuji M, Higashi S, Ebihara S, Nagata M (2024). Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience. https://pubmed.ncbi.nlm.nih.gov/38789831/
- Benjamin C, Crews R (2024). Nicotinamide Mononucleotide Supplementation: Understanding Metabolic Variability and Clinical Implications. Metabolites. https://pubmed.ncbi.nlm.nih.gov/38921475/
- Mills KF, Yoshida S, Stein LR, et al. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/28068222/
- Kawakami S, Maeda Y, Fukuzawa Y (2025). Intervention Study Comparing Blood NAD+ Concentrations with Liposomal and Non-Liposomal Nicotinamide Mononucleotide. Annals of Clinical and Medical Case Reports. https://acmcasereport.org/wp-content/uploads/2025/02/ACMCR-v14-2340-1.pdf
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Related reading
NAD+ and Lupus: NR Trials, Skin Studies and Evidence Limits
NR is being studied in lupus, while niacinamide has separate skin research. Understand the human evidence, ongoing trial and limits for systemic disease.
ReadNAD+ for Arthritis: What the Human Evidence Actually Tests
What arthritis studies actually show: a niacinamide osteoarthritis pilot, rheumatoid arthritis cell research and a 2026 NAD+ IV case report.
ReadNAD+ and Methylene Blue: Evidence, Interactions and Risks
Does combining NAD+ with methylene blue improve energy or cognition? What human studies show, where FDA approval applies, and why medication review matters.
ReadNMN for Diabetes: Insulin Sensitivity and Blood Sugar Evidence
What human NMN studies show about insulin sensitivity, glucose and HbA1c—and why a prediabetes signal is not a diabetes treatment.
ReadNAD+ and NMN for Hair Growth: What the Studies Tested
Hair-growth research on NMN, NAD+ and topical blends: what mice, follicle cells and human studies do—and do not—show about regrowth.
ReadNAD+ Dosage Guide: How Much Per Day, by Form and Route
What the human trials actually used for NR, NMN, niacin and nicotinamide — plus why the tidy injection and IV dosage charts online have no trial behind them.
Read